ArticleMolecules (Basel, Switzerland)2024
Myricetin Acts as an Inhibitor of Type II NADH Dehydrogenase from
Article in Molecules (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Cryptotanshinone inhibitsVirulence · 2026Article
- Phenolic Compounds: From Traditional Uses to Innovative Applications and Everything in Between.Molecular nutrition & food research · 2026Review
- Untargeted Metabolomics Reveals Color-Dependent Nutritional Variation in Raisins: Insights into Composition and Antioxidant Capacity.Antioxidants (Basel, Switzerland) · 2026Article
- Exploring myricetin: A comprehensive review of its pharmacological potential, formulation strategies, and clinical outlook.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Mechanisms of action of the hexane extract ofADMET & DMPK · 2026Article
- Inhibitors of NADH-O-methylquinone compound a class of antitubercular drugs.Molecular diversity · 2025Article
- Unlocking the Pharmacological Potential of Myricetin Against Various Pathogenesis.International journal of molecular sciences · 2025Review
- DisarmingPathogens (Basel, Switzerland) · 2025Review
- The protective effects and mechanism of myricetin in liver diseases (Review).Molecular medicine reports · 2025Review
- Inhibitors of Type II NADH Dehydrogenase Enzyme: A Review.Current protein & peptide science · 2025Review
- Metabolic Derangement of Essential Transition Metals and Potential Antioxidant Therapies.International journal of molecular sciences · 2024Review
- Breakthroughs in the development of antibiotics, antifungals and antiparasitics targeting the pathogens' respiratory chain.Critical reviews in biochemistry and molecular biologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
background
resultsA screening method was established to identify effective inhibitors of NDH-2, based on heterologously expressed
conclusionsMyricetin was newly discovered to be a competitive inhibitor of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.